Bosutinib (SKI-606)

Licensed by Pfizer Catalog No.S1014

Molecular Weight(MW): 530.45

Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively.

Cited by 19 Publications

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123

Blood, 2013, 122(7):1203-13

PubMed: 23836556

Blood, 2011, 118(7):1885-98

PubMed: 21680801

Cancer Res, 2016, 76(23):6937-6949

PubMed: 27758892

Cancer Res, 2012, 72(5):1229-38

PubMed: 22241084

Cancer Res, 2010, 70(19):7489-99

PubMed: 20709760

Mol Cancer Ther, 2017, pii: molcanther.0669

PubMed: 28223426

Mol Cancer Ther, 2016, 10.1158/1535-7163

PubMed: 27196758

J Virol, 2010, 85(5):2296-303

PubMed: 21177802

Biochim Biophys Acta, 2017, 1864(2):440-448

PubMed: 27913209

J Biol Chem, 2010, 285(11):7977-85

PubMed: 20068039

Mol Cell Biol, 2012, 32(2):320-32

PubMed: 22037769
Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131

Mol Hum Reprod, 2014, 10.1093/molehr/gau073

PubMed: 25180269

Int J Oncol, 2016, 49(1):402-10

PubMed: 27120977

Neurotox Res, 2015, 27(4):384-98

PubMed: 25782580

PLoS One, 2014, 9(1):e87014

PubMed: 24466315

PLoS One, 2014, 9(10):e111534

PubMed: 25356636

Anticancer Res, 2014, 34(4):1629-35

PubMed: 24692691

5 Customer Reviews

Both parental and HR cell lines were treated with bosutinib (0.01, 0.1, and 1 μmol/L) for 24 hours. Src-related signaling pathway molecules were then analyzed.

Mol Cancer Ther, 2017, 16(6):1145-1154. Bosutinib (SKI-606) purchased from Selleck.

Abl kinase phosphorylates MNRR1 in vivo. (A) K562 cells harboring the constitutively active BCR-ABL kinase when treated with 100 nM Bosutinib for 24 h show a reduction in MNRR1 phosphorylation. Lysates from vehicle and Bosutinib treated cells were immunoprecipitated using the anti-phosphotyrosine antibody and analyzed for the levels of MNRR1 in the precipitate. The IgG levels are also shown for an equal pull-down. Bosutinib efficacy was confirmed using antibodies against phospho-Abl kinase and phospho-STAT5, a downstream target of Abl kinase. Tubulin was used as a loading control. (B) Bosutinib treatment reduces the levels of phosphorylated proteins only. The total protein levels (Abl kinase and MNRR1) in vehicle and Bosutinib treated cells were similar. (C) Levels of Abl kinase in the WT and Abl kinase deficient MEFs (Abl^−/− MEFs). The doublet is caused by the presence of a non-specific band [28]. (D) The level of oxygen consumption in WT MEFs transfected with either WT or phosphomimetic Y99E mutant MNRR1. Oxygen consumption was measured in intact cells on a Seahorse Bioanalyzer. (E) Y99E mutant MNRR1 stimulates oxidative phosphorylation better than WT MNRR1 in Abl deficient MEFs (Abl^−/− MEFs) as measured by intact cellular oxygen consumption. (F) Bosutinib also inhibits BCR-Abl kinase in the mitochondrial fraction. NDUFS3 was used as a mitochondrial marker and GAPDH as a cytoplasmic marker to evaluate purity of the fractions. (G) K562 cells treated with Bosutinib, which show a reduction in the level of MNRR1 tyrosine phosphorylation (A), also have a reduction in the levels of oxygen consumption. (H) MNRR1 is not phosphorylated in the Abl^−/− MEFs. WT and Abl^−/− cellular lysates were immunoprecipitated with the anti-phosphotyrosine antibody and probed for the presence of MNRR1. The total levels of MNRR1 in the WT and Abl^−/− MEFs were similar.

Biochim Biophys Acta, 2017, 1864(2):440-448. Bosutinib (SKI-606) purchased from Selleck.
A,IC50 of Bosutinib that block ANDV-induced EC permeability. Endothelial cells were ANDV infected, and 3 days postinfection the permeability of cells in response to VEGF addition was determined in the presence or absence of increasing amounts of kinase inhibitor. The effect of inhibitors is presented as the percentage of ANDV-induced permeability of inhibitor-treated monolayers 3 days postinfection and 30 min post-VEGF and FITC-dextran addition. B, VEGFR2-Src inhibitors block ANDV-induced permeability. Endothelial cells were plated on vitronectin-coated Transwell inserts and infected at an MOI of 0.5 in triplicate with ANDV. Three days postinfection, the permeability of ANDV- and mock-infected endothelial cell monolayers was determined as described for Fig. 1 at indicated times in the presence or absence of Bosutinib .

J Virol 2011 85, 2296–2303. Bosutinib (SKI-606) purchased from Selleck.

SFK inhibitors abrogate tyrosine phosphorylation associated with sperm capacitation. Mouse sperm were incubated in the absence or in the presence of SKI606 for 60 min in capacitating (cap, with HCO3) or non-capacitating media (NC, without HCO3). Western blot analyses were performed withanti-pY antibodies.

J Biol Chem 2010 285, 7977–7985. Bosutinib (SKI-606) purchased from Selleck.
Rescue ofPKAand tyrosine phosphorylation by Ser/Thr phosphatase inhibitors. A and B, spermwere incubated in capacitating medium supplemented with SFK inhibitors and different concentrations of okadaic acid (OA) (A) or calyculin-A (B), before immunodetection of p-PKA substrates (clone 100G7E). C and D, PVDF membranes used in A and B were stripped as described and used for Western blot immunodetection with anti-PY antibodies (clone 4G10).

Dr. Pablo E.Visconti from University of Massachusetts. Bosutinib (SKI-606) purchased from Selleck.

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description

Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively.

Targets

Abl ^[2] (Cell-free assay)	Src ^[1] (Cell-free assay)
1 nM	1.2 nM

In vitro

Bosutinib is selective for Src over non-Src family kinases with an IC50 of 1.2 nM, and potently inhibits Src-dependent cell proliferation with an IC50 of 100 nM. ^[1] Bosutinib significantly inhibits the proliferation of Bcr-Abl-positive leukemia cell lines KU812, K562, and MEG-01 but not Molt-4, HL-60, Ramos, and other leukemia cell lines, with IC50 of 5 nM, 20 nM and 20 nM, respectively, more potently than that of STI-571. Similar to STI-571, Bosutinib displays antiproliferative activity against the Abl-MLV-transformed fibroblasts with IC50 of 90 nM. Bosutinib ablates tyrosine phosphorylation of Bcr-Abl and STAT5 in CML cells and of v-Abl expressed in fibroblasts at the concentration of ~50 nM, 10-25 nM and 200 nM, respectively, leading to the Bcr-Abl downstream signaling inhibition of Lyn/Hck phosphorylation. ^[2] Although unable to inhibit the proliferation and survival of breast cancer cells, Bosutinib significantly decreases the motility and invasion of breast cancer cells with IC50 of ~250 nM, involved with an increase in cell-to-cell adhesion and membrane localization of β-catenin. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
NB7	NF2xellIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTBwMEiyN\|EhKM7:TR?=	NXTXb5FEW0GQR1XS
SW756	NV75fWs6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVzJR\|UxRTBwMUSwNlQhKM7:TR?=	M{Pp[XNCVkeHUh?=
CTV-1	NX3oSHlMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTBwMU[zPVghKM7:TR?=	MoHxV2FPT0WU
HSC-4	NXixeXQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIr5RlNKSzVyPUCuNVcyPThiIN88US=>	M3vEUnNCVkeHUh?=
LAMA-84	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2D4fmlEPTB;MD6yPFY3PCBizszN	NG\PWHhUSU6JRWK=
KU812	NUGxfY1MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYrsPGZ6UUN3ME2wMlM1ODZ6IDFOwG0>	NWPw[Zk2W0GQR1XS
HCC1806	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTBwM{WyNVYhKM7:TR?=	MlfhV2FPT0WU
DOK	NIrGdVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTBwM{e3PFYhKM7:TR?=	M3zyXXNCVkeHUh?=
NCI-H209	Ml\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTBwNEC4NFghKM7:TR?=	NVfoSW1TW0GQR1XS
EoL-1-cell	MlnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLsVJFKSzVyPUCuOFE2PzZiIN88US=>	MmX1V2FPT0WU
H9	M2fQfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\GSWZEUUN3ME2wMlQ{PDZ2IDFOwG0>	NGLhRZFUSU6JRWK=
EM-2	NULBU5NqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MofxTWM2OD1yLkSzPFkhKM7:TR?=	MYTTRW5ITVJ?
NCI-H292	M17Xc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLNNVJKSzVyPUCuOFQyODhiIN88US=>	M1zaWXNCVkeHUh?=
697	NXvpO4FYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTBwNEW2N\|MhKM7:TR?=	MnTjV2FPT0WU
BHT-101	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFz1RolKSzVyPUCuOFY2QSBizszN	NFnOPFlUSU6JRWK=
BE-13	MnTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXW5[YdsUUN3ME2wMlQ5PTd{IDFOwG0>	NFLRVm9USU6JRWK=
RS4-11	NEC5XoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4LreWlEPTB;MD60PFU5PCBizszN	MmrtV2FPT0WU
IGROV-1	NFWyZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoP4TWM2OD1yLkS4O\|k4KCEQvF2=	M1T4SnNCVkeHUh?=
KE-37	MmXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHZUo9KSzVyPUCuOFk2ODliIN88US=>	MmXHV2FPT0WU
BV-173	NWfGNoFJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nRVGlEPTB;MD61NFc6OiBizszN	M2P3e3NCVkeHUh?=
MEG-01	MmnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmLiTWM2OD1yLkWxNlE1KCEQvF2=	MWrTRW5ITVJ?
LB2241-RCC	NHy4bJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofZTWM2OD1yLkWzO\|E5KCEQvF2=	NHe3dI9USU6JRWK=
ACHN	NVi0WXAxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoD1TWM2OD1yLkW0NFY6KCEQvF2=	NXrOSFBKW0GQR1XS
CTB-1	MlzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDuTnliUUN3ME2wMlU1QDJiIN88US=>	MnzqV2FPT0WU
HT-1080	M3PGemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3HYWWlEPTB;MD61OVM1QSBizszN	MlLLV2FPT0WU
CHL-1	NEHv[25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\n[4c4UUN3ME2wMlU2PDZ3IDFOwG0>	M{DzTnNCVkeHUh?=
EW-3	MmPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTkV3h3UUN3ME2wMlU2QTN3IDFOwG0>	M3HOR3NCVkeHUh?=
ES1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTBwNke0PVghKM7:TR?=	M2fVe3NCVkeHUh?=
KASUMI-1	M4eyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGe2NYVKSzVyPUCuO\|I{OyBizszN	MnLDV2FPT0WU
SW13	NVT1dVZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH:3em1KSzVyPUCuO\|M4QThiIN88US=>	MnPUV2FPT0WU
A3-KAW	NY\Sc4R2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmqzTWM2OD1yLke5NlA5KCEQvF2=	NXPSfm1yW0GQR1XS
LB771-HNC	NGrwOY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fE[mlEPTB;MD64N\|ExPCBizszN	NV\BO25sW0GQR1XS
OC-314	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnKbZpGUUN3ME2wMlg3QTZ3IDFOwG0>	MWTTRW5ITVJ?
MLMA	NFr0UHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTTO45JUUN3ME2wMlkxPjd3IDFOwG0>	NYnOTXJqW0GQR1XS
KARPAS-45	NWjyZ3Z{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTBwOUK0OlYhKM7:TR?=	M2TWWnNCVkeHUh?=
CAL-27	M4DOOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{T3R2lEPTB;MD65NlkxPiBizszN	MYLTRW5ITVJ?
SK-NEP-1	M3i5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PNOGlEPTB;MD65O\|I1QCBizszN	NGficmpUSU6JRWK=
COR-L105	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTFwMECzPVQhKM7:TR?=	MUTTRW5ITVJ?
TI-73	MkS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTFwMEG2OUAh\|ryP	MYDTRW5ITVJ?
JVM-3	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PBcmlEPTB;MT6wOVAyPyBizszN	NY[wVohQW0GQR1XS
HAL-01	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1H0WmlEPTB;MT6wPFgyKCEQvF2=	NUO1OGhjW0GQR1XS
QIMR-WIL	MnHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVTuXZcyUUN3ME2xMlA6ODV6IDFOwG0>	NIC3PVlUSU6JRWK=
HSC-3	NILk[2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;GNYt[UUN3ME2xMlEyPzh\|IDFOwG0>	MX;TRW5ITVJ?
KY821	M{HhZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULEXHliUUN3ME2xMlE{OzVzIDFOwG0>	NFPuS2FUSU6JRWK=
5637	M2rWPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTFwMUO4NFMhKM7:TR?=	M17LTXNCVkeHUh?=
CAL-33	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mof5TWM2OD1zLkG5N\|AzKCEQvF2=	MnTpV2FPT0WU
ES4	Mn;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PqUWlEPTB;MT6yNFc6KCEQvF2=	M{HqdXNCVkeHUh?=
BHY	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7CbZNLUUN3ME2xMlIzQDl{IDFOwG0>	NV7hcIY3W0GQR1XS
LB1047-RCC	NIrmSmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\IbW1KSzVyPUGuNlM4QDViIN88US=>	MY\TRW5ITVJ?
H4	NVLJU\|FJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2O3RmlEPTB;MT6yOFI2PSBizszN	M3;tdHNCVkeHUh?=
RPMI-8866	MmLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\jTWM2OD1zLkK2NVA3KCEQvF2=	MWPTRW5ITVJ?
HO-1-N-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\SU2xKSzVyPUGuNlY{PjliIN88US=>	MmiwV2FPT0WU
BB30-HNC	NFTUbnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTFwMki3NVQhKM7:TR?=	MmXkV2FPT0WU
PC-14	MoP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEL5fWtKSzVyPUGuNlkzODViIN88US=>	M2fLRnNCVkeHUh?=
NUGC-3	M1PYTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1nQXmlEPTB;MT6yPVM2PiBizszN	M{S3TnNCVkeHUh?=
A4-Fuk	MmSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVP3VFlvUUN3ME2xMlMxPzB2IDFOwG0>	NWLLZopRW0GQR1XS
MHH-NB-11	NInXXmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXJeIlKSzVyPUGuN\|E{QDNiIN88US=>	M{jJeHNCVkeHUh?=
KOSC-2	Ml7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2DxPWlEPTB;MT6zNVc4PSBizszN	NV\2emJtW0GQR1XS
A498	NX;JNYd1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDreoZOUUN3ME2xMlQxOTF\|IDFOwG0>	M{nDRXNCVkeHUh?=
KG-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTFwNEGyO\|MhKM7:TR?=	NEnRO\|JUSU6JRWK=
DEL	NX\rWG1rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLtTWM2OD1zLkSzOlU4KCEQvF2=	Mnm4V2FPT0WU
EW-16	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYiwXW1oUUN3ME2xMlQ{QTd\|IDFOwG0>	NXfXRpVTW0GQR1XS
BPH-1	NEXJdpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkDvTWM2OD1zLkS0PFA2KCEQvF2=	NYjtPHlVW0GQR1XS
JAR	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLsb\|hNUUN3ME2xMlQ6OzZiIN88US=>	MkTXV2FPT0WU
J-RT3-T3-5	NE\kXXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzQR\|BKSzVyPUGuOVE4OjJiIN88US=>	MY\TRW5ITVJ?
A375	M3e1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTFwNUG3O\|IhKM7:TR?=	MVLTRW5ITVJ?
SW954	M{Czc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPwTWM2OD1zLkW1NFA4KCEQvF2=	MnTjV2FPT0WU
Ca9-22	NGDNbodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGP1dFBKSzVyPUGuOVYzPiBizszN	MlTmV2FPT0WU
D-566MG	MojZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;VRmFKSzVyPUGuOVcyPTViIN88US=>	NHXVdoVUSU6JRWK=
SCC-15	NFH6T3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTFwNkG4NFQhKM7:TR?=	MVPTRW5ITVJ?
HD-MY-Z	M2nBRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXnJR\|UxRTFwNkO1PFQhKM7:TR?=	MXfTRW5ITVJ?
HT-1376	MkjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIC0S4VKSzVyPUGuOlQ{PiBizszN	Ml70V2FPT0WU
CAL-54	M3;GPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3k[ZZKSzVyPUGuOlU4ODliIN88US=>	M2fDUnNCVkeHUh?=
ONS-76	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnH[WpGUUN3ME2xMlY4PTVzIDFOwG0>	NEe2bIRUSU6JRWK=
EFO-27	NYLzeYNUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4W4WWlEPTB;MT62PFkzKCEQvF2=	NYP1XpBwW0GQR1XS
769-P	NH\5SIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nUNmlEPTB;MT62PVU6PiBizszN	NWLqRoVkW0GQR1XS
MV-4-11	NYG4SJNbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PrZmlEPTB;MT62PVg2PiBizszN	MoXQV2FPT0WU
NKM-1	M1vWfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\0V2lEPTB;MT63NVgxOiBizszN	MVjTRW5ITVJ?
LOXIMVI	NHS5U4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7SVWRKSzVyPUGuO\|Q2QTliIN88US=>	NHXvXYZUSU6JRWK=
KYSE-140	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnPuTWM2OD1zLke1OlU2KCEQvF2=	NXHNcXFCW0GQR1XS
ES5	NIX2UmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTFwOE[3OFchKM7:TR?=	MmrPV2FPT0WU
BB65-RCC	MlvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHfTXmdKSzVyPUGuPFk5PDliIN88US=>	NW\yNFR1W0GQR1XS
HN	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jkc2lEPTB;MT64PVg4PCBizszN	MWDTRW5ITVJ?
A101D	NIXTWXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTFwOUO2NlghKM7:TR?=	NFO4V21USU6JRWK=
LoVo	NXPRNHB5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGKxOoJKSzVyPUGuPVc3PzliIN88US=>	NWDZU5BZW0GQR1XS
NCI-H526	M2q1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHCTWM2OD1zLkm5N\|I2KCEQvF2=	NVHXXXczW0GQR1XS
NCI-H1693	MlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTFwOUm4PFghKM7:TR?=	MX3TRW5ITVJ?
OVCAR-4	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTJwMEC0N\|UhKM7:TR?=	NYLnZZhKW0GQR1XS
SK-HEP-1	NGTQUZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jXPWlEPTB;Mj6wNFc1PSBizszN	NWHqO2lLW0GQR1XS
C2BBe1	NFzPeI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjx[41pUUN3ME2yMlA{Ozd{IDFOwG0>	MUPTRW5ITVJ?
MEL-JUSO	MonLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWrzSnlbUUN3ME2yMlA1PDZ2IDFOwG0>	NWLTNlR2W0GQR1XS
MOLT-16	MlH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvvTWM2OD1{LkC3NFU5KCEQvF2=	NGLjVYFUSU6JRWK=
NBsusSR	Ml3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTJwMEm4PFkhKM7:TR?=	NYOzSY1lW0GQR1XS
TK10	NXX2dVcxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH2ydJBKSzVyPUKuNVM1PThiIN88US=>	NWf3ZlI1W0GQR1XS
CAL-39	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlzOTWM2OD1{LkG0OFghKM7:TR?=	NEnUS5NUSU6JRWK=
NCI-H2030	NYfsSGlqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDNNFNYUUN3ME2yMlE5QTd\|IDFOwG0>	NY\vSnZLW0GQR1XS
HCT-116	NF;BdJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\HeZpKSzVyPUKuNlI6QDRiIN88US=>	M{jZRXNCVkeHUh?=
HTC-C3	MnjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGD0S49KSzVyPUKuNlY5OjRiIN88US=>	MV3TRW5ITVJ?
TYK-nu	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjZTmtmUUN3ME2yMlMxQTB7IDFOwG0>	NE\tO2dUSU6JRWK=
FADU	NEDmZ3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fHZmlEPTB;Mj6zNlI6PiBizszN	M17Q[3NCVkeHUh?=
A431	M3\pdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVSwb3FwUUN3ME2yMlM4ODJ3IDFOwG0>	NHL4TllUSU6JRWK=
TE-11	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1G1PWlEPTB;Mj6zPFAyQSBizszN	NEm4OlVUSU6JRWK=
CAL-12T	NH3VWIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3P4VWlEPTB;Mj60NFQyPyBizszN	MWXTRW5ITVJ?
DB	MnLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTJwNEK4OlkhKM7:TR?=	NF7GTlVUSU6JRWK=
L-363	NH61WYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTJwNEO1NFchKM7:TR?=	NVPYUXViW0GQR1XS
MSTO-211H	MnO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTJwNk[zPVEhKM7:TR?=	NWTQ[opDW0GQR1XS
SK-UT-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;N[FNKSzVyPUKuO\|E1ODZiIN88US=>	NFGzb3BUSU6JRWK=
RPMI-8226	NUHPRlU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{fmcmlEPTB;Mj63N\|E3PCBizszN	Mm\yV2FPT0WU
SF295	NH7zPFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fJ[WlEPTB;Mj63OFMyKCEQvF2=	MmXtV2FPT0WU
OS-RC-2	M2[xWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljPTWM2OD1{Lke2Olc{KCEQvF2=	MlfhV2FPT0WU
SK-MEL-24	NHLTNY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHCTWM2OD1{Lke4NlI1KCEQvF2=	NIH1cmdUSU6JRWK=
COR-L23	M1rnTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknQTWM2OD1{Lke5OFY1KCEQvF2=	M1naNHNCVkeHUh?=
MHH-PREB-1	Mlf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXP4ZnNCUUN3ME2yMlgxOTZzIDFOwG0>	NEPsPGxUSU6JRWK=
SK-N-DZ	NXvpW5ExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTJwOEG2N\|ghKM7:TR?=	NEP1V5ZUSU6JRWK=
OMC-1	MkLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDYTWM2OD1{Lki1NFA{KCEQvF2=	NVH6UmRQW0GQR1XS
SK-MEL-2	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfRZ\|I3UUN3ME2yMlg6OjR\|IDFOwG0>	Mn\jV2FPT0WU
SAS	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjMR\|lKSzVyPUKuPVk1OTViIN88US=>	Mni5V2FPT0WU
EPLC-272H	NF\FRYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTNwMECyN\|UhKM7:TR?=	MlewV2FPT0WU
8505C	MlTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NViyWZk1UUN3ME2zMlExOzBzIDFOwG0>	NV\n[GhoW0GQR1XS
EW-11	M2TUNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13w[mlEPTB;Mz6xOFI4PyBizszN	NVnLPXNXW0GQR1XS
YKG-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVX4XFhvUUN3ME2zMlE1PzB4IDFOwG0>	NYnnRWNPW0GQR1XS
EC-GI-10	M3LnTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{nMVGlEPTB;Mz6xO\|I3OyBizszN	MoPsV2FPT0WU
SK-LU-1	NHLydHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTNwMUi0NVghKM7:TR?=	MonsV2FPT0WU
P30-OHK	NHnt[oJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33WSWlEPTB;Mz6yNFEyPyBizszN	M2TPW3NCVkeHUh?=
T-24	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2XxeWlEPTB;Mz6yNVgyPCBizszN	NWfWSXo5W0GQR1XS
HSC-2	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfJcWdkUUN3ME2zMlIzOjN{IDFOwG0>	NW\C[GpiW0GQR1XS
SK-MES-1	NVezc2pwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjRN5ZXUUN3ME2zMlI1QDJ7IDFOwG0>	NGDVXJFUSU6JRWK=
SW48	NG\F[WRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7iTWM2OD1\|LkK1OFg3KCEQvF2=	M3jRZnNCVkeHUh?=
ME-180	Mk\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojaTWM2OD1\|LkK2NFUyKCEQvF2=	NUfXR\|JiW0GQR1XS
NCI-H2009	M4faNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUP6[3RGUUN3ME2zMlI6ODFiIN88US=>	NGexPIdUSU6JRWK=
HL-60	M{XL[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M124eWlEPTB;Mz6yPVE{KCEQvF2=	M17UenNCVkeHUh?=
NCI-N87	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{iwV2lEPTB;Mz6zNFE4OiBizszN	NH3IVZhUSU6JRWK=
GMS-10	M1nVd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTNwM{SwPFYhKM7:TR?=	MlTRV2FPT0WU
SCH	NUOxXoJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTNwNEC4OFQhKM7:TR?=	MXTTRW5ITVJ?
C-33-A	NIfTWFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\TcWlEPTB;Mz60NVQzOSBizszN	NWDoc4JZW0GQR1XS
NCI-H1703	MmXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXOWVA1UUN3ME2zMlQyQDF{IDFOwG0>	M2LFPXNCVkeHUh?=
A427	NFHTcmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTNwNE[xNlQhKM7:TR?=	Ml\sV2FPT0WU
MOLT-4	NGDicIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXl[G03UUN3ME2zMlQ5OTl7IDFOwG0>	NVf4XHlOW0GQR1XS
NCI-H1792	NI\WXIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2e0RWlEPTB;Mz60PVgxOiBizszN	MWPTRW5ITVJ?
NCI-H1650	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTNwNUeyPUAh\|ryP	NHfhRnRUSU6JRWK=
H-EMC-SS	NHrCWlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIH6bXdKSzVyPUOuOVg2PjliIN88US=>	MX7TRW5ITVJ?
SW982	M4LVXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3HncGlEPTB;Mz61PFgzQSBizszN	M1TrZnNCVkeHUh?=
DSH1	M1LQWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHf4eo5KSzVyPUOuOlQyOjJiIN88US=>	NXH2T3BCW0GQR1XS
NOS-1	M1:yXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTNwNkSyO\|YhKM7:TR?=	MX;TRW5ITVJ?
BT-549	M4PPT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2XoZmlEPTB;Mz62O\|g2PCBizszN	M37pVHNCVkeHUh?=
HuCCT1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTNwN{SxO\|chKM7:TR?=	MV;TRW5ITVJ?
NCI-H1755	MnvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDIfIdKSzVyPUOuPVY6PzFiIN88US=>	NVW1XYsyW0GQR1XS
KYSE-450	NFXwcIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnSxTWM2OD1\|Lkm2PVk4KCEQvF2=	MonFV2FPT0WU
MIA-PaCa-2	MoLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4i2RmlEPTB;Mz65O\|I6KCEQvF2=	NEnVWY9USU6JRWK=
U-266	MnriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXwOndKSzVyPUOuPVc1QDFiIN88US=>	MX\TRW5ITVJ?
Mewo	M37pUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTRwME[zOlEhKM7:TR?=	NF3afZpUSU6JRWK=
KYSE-520	NH\lcHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTRwMEm3PVkhKM7:TR?=	NXLHNI1kW0GQR1XS
MN-60	NVXyWoJoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVnsVnlOUUN3ME20MlExPTBzIDFOwG0>	M3rXbXNCVkeHUh?=
Ramos-2G6-4C10	NYi5clZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTRwMU[3N\|khKM7:TR?=	NEjtU2xUSU6JRWK=
SK-MEL-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\Ed2hKSzVyPUSuNVg3QTViIN88US=>	MoLLV2FPT0WU
ABC-1	NWXKXoExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH7WTIlKSzVyPUSuNlM{OzNiIN88US=>	M{jPXHNCVkeHUh?=
CAKI-1	M4Pjfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUDJR\|UxRTRwMkS1O\|EhKM7:TR?=	MkXOV2FPT0WU
HOS	NVK0eJpRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLwSIJyUUN3ME20MlI6OTRzIDFOwG0>	MWXTRW5ITVJ?
SN12C	NX25cYJRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;GbmlEPTB;ND6zOFI1PCBizszN	M3r4NHNCVkeHUh?=
NB13	Mn:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVTvXnB2UUN3ME20MlM4OzV3IDFOwG0>	M2HXVXNCVkeHUh?=
M14	NX3KPGFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTRwNEi3PVIhKM7:TR?=	MV\TRW5ITVJ?
GP5d	NV34cXA3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnhNFVzUUN3ME20MlUxOTJiIN88US=>	MlXoV2FPT0WU
NCI-H720	MoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrvTHdKSzVyPUSuOVM3OTJiIN88US=>	NEHmWnFUSU6JRWK=
D-423MG	MonwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPVfHZKSzVyPUSuOVM6OjRiIN88US=>	MmHWV2FPT0WU
ChaGo-K-1	M1fwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml36TWM2OD12LkW5OVU6KCEQvF2=	NF7X[5FUSU6JRWK=
MEL-HO	M{XqO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLZTWM2OD12Lk[xNlYyKCEQvF2=	M{jTSHNCVkeHUh?=
MHH-ES-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHZO5dKSzVyPUSuOlI1OTFiIN88US=>	NX7rSldxW0GQR1XS
KYSE-270	NWGzUZVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\tS2lKSzVyPUSuOlUyOjZiIN88US=>	MmfvV2FPT0WU
GI-ME-N	M1\kZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfKPFJKSzVyPUSuO\|EzQTFiIN88US=>	NFXncY1USU6JRWK=
HOP-92	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvHTWM2OD12LkixN\|c6KCEQvF2=	NILqbYNUSU6JRWK=
MKN1	MlfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HGOmlEPTB;ND64N\|kyPCBizszN	M{XVUHNCVkeHUh?=
ML-2	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HFT2lEPTB;ND64OVYzPiBizszN	MXvTRW5ITVJ?
RO82-W-1	NWHWUIJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDlTWM2OD12LkmyPVghKM7:TR?=	NF\kdIdUSU6JRWK=
G-361	M37kWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;6SIRKSzVyPUWuNFExODNiIN88US=>	NGr4WphUSU6JRWK=
HC-1	MoXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUi3WZlwUUN3ME21MlA{OjlzIDFOwG0>	M4j5VXNCVkeHUh?=
EW-24	NELYTI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGL2bWxKSzVyPUWuNFQxOzhiIN88US=>	MonBV2FPT0WU
HuP-T4	M3jjNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13w[2lEPTB;NT6xOFM{PCBizszN	NFHhdpNUSU6JRWK=
8-MG-BA	NHnZcohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnaXmRKSzVyPUWuN\|QzQCBizszN	MlvZV2FPT0WU
HGC-27	NVv1cFhnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;CcGlEPTB;NT6zO\|Y5OiBizszN	M3TxOHNCVkeHUh?=
TE-12	M4fXPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfNTVQ5UUN3ME21MlQyPTh3IDFOwG0>	M1fQOXNCVkeHUh?=
GT3TKB	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2f3dmlEPTB;NT60OFIyOiBizszN	M3z2fHNCVkeHUh?=
DOHH-2	M4rQc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vDTWlEPTB;NT60OVk5PiBizszN	NXrrSVcxW0GQR1XS
Ca-Ski	MkL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfMU5JKSzVyPUWuOFYyOTViIN88US=>	NV32VVJCW0GQR1XS
A172	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{S1bmlEPTB;NT61OFkzPSBizszN	M1jDcXNCVkeHUh?=
EGI-1	M4\zT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIL0cJhKSzVyPUWuOVg6OzhiIN88US=>	NYT1VmRxW0GQR1XS
MZ2-MEL	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{TiTmlEPTB;NT62NVQ5PiBizszN	NHvu[2FUSU6JRWK=
SW1710	MmD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2K3OGlEPTB;NT62PVA6OSBizszN	NYHqZ\|NlW0GQR1XS
HT-144	NYLHZ2FET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEn2TmVKSzVyPUWuO\|I3QDViIN88US=>	NFPxb5lUSU6JRWK=
PA-1	M4W4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXnJR\|UxRTVwOEG4PVMhKM7:TR?=	NX;jPJFEW0GQR1XS
HCC1937	NH;vRllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTVwOEO5NlkhKM7:TR?=	MUfTRW5ITVJ?
SK-OV-3	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkX6TWM2OD13LkmxNVIyKCEQvF2=	NXvaTINOW0GQR1XS
K5	NYC5dGZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX73dHBtUUN3ME22MlA2OTdiIN88US=>	NGHyUW9USU6JRWK=
NMC-G1	MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTZwMEe3PVchKM7:TR?=	NWLpR5czW0GQR1XS
MDA-MB-361	NYnIclNRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LoVWlEPTB;Nj6wPVI3OSBizszN	NIPpZVdUSU6JRWK=
EKVX	NWmyXJdTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnaTWM2OD14LkGzOVAyKCEQvF2=	MVjTRW5ITVJ?
ES7	NGHwSlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1SxUmlEPTB;Nj6xOlEyPSBizszN	NImzbmlUSU6JRWK=
KS-1	NGH0bWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoG0TWM2OD14LkG3PVk{KCEQvF2=	Mo\mV2FPT0WU
NCI-H661	NHXQO5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnLFTWM2OD14LkG4NFgyKCEQvF2=	M{LmZ3NCVkeHUh?=
ES8	M4npWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTZwMUiwPFIhKM7:TR?=	Mlf6V2FPT0WU
NCI-H23	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\1ZlFOUUN3ME22MlIyQDF4IDFOwG0>	MmHaV2FPT0WU
T47D	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MorhTWM2OD14LkK2OFU4KCEQvF2=	M4C3R3NCVkeHUh?=
A2780	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3P[HRKSzVyPU[uN\|c4ODFiIN88US=>	MVnTRW5ITVJ?
SCC-4	NEPndoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\MWItKSzVyPU[uOFM2PjFiIN88US=>	NYLRWIdzW0GQR1XS
VA-ES-BJ	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofxTWM2OD14Lkm3NFQ{KCEQvF2=	M{CzT3NCVkeHUh?=
no-11	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4qzSWlEPTB;Nz6xOlQyKCEQvF2=	NHrRTGJUSU6JRWK=
KU-19-19	NWTibYNJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInIWmFKSzVyPUeuNVY1PzZiIN88US=>	NFvzW3hUSU6JRWK=
MKN45	M1;oXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fxSmlEPTB;Nz6xPFY6QSBizszN	Mkj0V2FPT0WU
SCC-25	NHzmTIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkjKTWM2OD15LkKzOFE1KCEQvF2=	NUH6cG5FW0GQR1XS
ETK-1	M1HYN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXI[VBKSzVyPUeuNlU2OTRiIN88US=>	NGL1XlRUSU6JRWK=
COR-L88	NXnyNVZzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTdwMkmzNVkhKM7:TR?=	MmLjV2FPT0WU
8305C	NV34elJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXwWmlKSzVyPUeuN\|I1QTJiIN88US=>	NELScmVUSU6JRWK=
Detroit562	Mo\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLBSoVxUUN3ME23MlMzPTB4IDFOwG0>	MWTTRW5ITVJ?
SNU-449	MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;MTWM2OD15LkO3OlUyKCEQvF2=	NGeyOZhUSU6JRWK=
A704	NF24WFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPkZWFqUUN3ME23MlM5Ojd6IDFOwG0>	NYrTW3VNW0GQR1XS
D-502MG	NIrNNJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTFfJFKSzVyPUeuN\|g1PzNiIN88US=>	NWXLOpJjW0GQR1XS
NCI-H2228	NYrrXGw5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MofZTWM2OD15LkSxOFU5KCEQvF2=	NWqyV4xVW0GQR1XS
CHP-212	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYr1RWY{UUN3ME23MlUyQDl4IDFOwG0>	MXnTRW5ITVJ?
VMRC-RCZ	NW\hSXMzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml7hTWM2OD15LkW5NFY3KCEQvF2=	MYrTRW5ITVJ?
RPMI-2650	Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPETlVKSzVyPUeuO\|A{OTJiIN88US=>	MkTxV2FPT0WU
HCC2218	MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfDTWM2OD15LkeyNlU5KCEQvF2=	NYnBb3hMW0GQR1XS
GCT	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTdwOEKxO\|IhKM7:TR?=	M1nmWXNCVkeHUh?=
SW780	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTdwOUmwOkAh\|ryP	NV7s[phPW0GQR1XS
KMOE-2	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2XoTGlEPTB;OD6wOFA4KCEQvF2=	M1nMZ3NCVkeHUh?=
KYSE-180	MoTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRThwMEi2OFghKM7:TR?=	M3TYOnNCVkeHUh?=
TE-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3LCUmlEPTB;OD6xNVA2PyBizszN	MlzSV2FPT0WU
OAW-42	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;pU2tKSzVyPUiuNlU1QTZiIN88US=>	Mn33V2FPT0WU
VM-CUB-1	NH3Ie4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3POU2lEPTB;OD6yPFM3PCBizszN	MnPMV2FPT0WU
ECC10	NXq3W2tVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTaWIRKSzVyPUiuNlg{QTdiIN88US=>	MXrTRW5ITVJ?
SW1573	NFfPZ3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\qZWVxUUN3ME24MlQ1PDZ3IDFOwG0>	NEW1bHhUSU6JRWK=
NCI-H1299	NHXvUVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYP5[FM6UUN3ME24MlU6Pzd2IDFOwG0>	M3fwPXNCVkeHUh?=
ALL-PO	Mnr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF3nVVRKSzVyPUiuOlY2QTdiIN88US=>	NWHjXoxlW0GQR1XS
OVCAR-5	M3LKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\FPYh4UUN3ME24Mlc4PjJ3IDFOwG0>	MX;TRW5ITVJ?
NCI-SNU-5	NITXdVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\FWmlEPTB;OD64N\|AxOSBizszN	NH\zN5RUSU6JRWK=
NCI-H2342	MnHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRThwOEOxNFEhKM7:TR?=	NEHWSm9USU6JRWK=
RPMI-7951	M4f0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGKzUFhKSzVyPUiuPFQyPTdiIN88US=>	MoTkV2FPT0WU
RCM-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfaTVdPUUN3ME25MlA5OTR3IDFOwG0>	MnPKV2FPT0WU
Daoy	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHuR4V2UUN3ME25MlEzODJ6IDFOwG0>	NVqyd\|VsW0GQR1XS
HCC1395	MlHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVy4SoNuUUN3ME25MlMxQDl4IDFOwG0>	MWnTRW5ITVJ?
786-0	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTlwM{[wNlYhKM7:TR?=	MXHTRW5ITVJ?
GAMG	NV3n[GNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPXTWM2OD17Lk[1OVM1KCEQvF2=	NY[wW3NjW0GQR1XS
HCC1954	NW\qXmNpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjJcXc{UUN3ME25Mlg2QDV7IDFOwG0>	MnS1V2FPT0WU
NCI-H1838	NWm4RYhZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTlwOUCzO\|EhKM7:TR?=	MYLTRW5ITVJ?
SW620	MmSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIP0Z5VKSzVyPUmuPVU{PTdiIN88US=>	MkPaV2FPT0WU
NCI-H358	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkDITWM2OD1zMD60NVk4KCEQvF2=	NYTkUnhIW0GQR1XS
NCI-H1793	MoX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjVOJBMUUN3ME2xNE41OjR6IDFOwG0>	MmntV2FPT0WU
NCI-H1666	MmKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLKW4VOUUN3ME2xNE41OzV3IDFOwG0>	MmDGV2FPT0WU
MZ7-mel	M{nW[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXyfWR7UUN3ME2xNE41PzV\|IDFOwG0>	MnK0V2FPT0WU
MDA-MB-175-VII	M2LJRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jrS2lEPTB;MUCuOlM6PiBizszN	MYTTRW5ITVJ?
COLO-829	M3LqcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfPPGdKSzVyPUGwMlgxODRiIN88US=>	MX3TRW5ITVJ?
RVH-421	NFzUVGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGj1bZVKSzVyPUGxMlE2OiBizszN	NWDkZYUyW0GQR1XS
A549	NVP2doFnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTFzLkK0O\|ghKM7:TR?=	M1vNbXNCVkeHUh?=
DJM-1	M2r6ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHWxPJZKSzVyPUGxMlM5OzNiIN88US=>	NVuwNIRPW0GQR1XS
IST-MEL1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoriTWM2OD1zMT63N\|E6KCEQvF2=	MVPTRW5ITVJ?
BEN	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHX1OGNKSzVyPUGxMlc1ODJiIN88US=>	M4\hOXNCVkeHUh?=
KM12	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1PVS2lEPTB;MUGuPVA6OSBizszN	NEX3TpFUSU6JRWK=
HuO9	M3;rSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfRTWM2OD1zMj6wOlY3KCEQvF2=	M2jxU3NCVkeHUh?=
U-2-OS	M130[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHrlTnRKSzVyPUGyMlA5QTNiIN88US=>	NVrpSHNNW0GQR1XS
RH-1	M2\sXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTF{LkS0O\|IhKM7:TR?=	NWTLfmtsW0GQR1XS
NCI-H1048	M322Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LhUmlEPTB;MUKuOVUxPiBizszN	MXvTRW5ITVJ?
Mo-T	NYPYb4tzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTF{LkezNFchKM7:TR?=	NISydIFUSU6JRWK=
KYSE-150	NUPsNWVkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvzXYxKSzVyPUGyMlc1PTViIN88US=>	NIjreZdUSU6JRWK=
A388	MmG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWHodohJUUN3ME2xNk44PzF\|IDFOwG0>	M2LYOXNCVkeHUh?=
NCI-SNU-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;YTWM2OD1zMj64NFQ3KCEQvF2=	MmPQV2FPT0WU
HEL	MnPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTF{LkiyNVIhKM7:TR?=	Mm\uV2FPT0WU
UM-UC-3	MmTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUT1XXBJUUN3ME2xNk45QDd2IDFOwG0>	NVr5fpVlW0GQR1XS
TGBC24TKB	NULjdXd3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jpbWlEPTB;MUOuNFI3PyBizszN	MVTTRW5ITVJ?
SW626	M3r4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjuNpJMUUN3ME2xN{4zPDh3IDFOwG0>	MlflV2FPT0WU
ES6	NHfa[5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTF\|LkK1NVIhKM7:TR?=	NXjXTlVbW0GQR1XS
NCI-H2029	M3\EUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3:yc2lEPTB;MUOuPFExQCBizszN	NET6cGtUSU6JRWK=
RXF393	MomwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnGTWM2OD1zMz65PVI4KCEQvF2=	MW\TRW5ITVJ?
HMV-II	NEXEUYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XEc2lEPTB;MUSuNFc5KCEQvF2=	M3fiWHNCVkeHUh?=
EW-22	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXr1fYpqUUN3ME2xOE4yPTB{IDFOwG0>	MonVV2FPT0WU
AsPC-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHCfYNKSzVyPUG0MlU3PCBizszN	MYDTRW5ITVJ?
COLO-678	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTF2LkeyO\|EhKM7:TR?=	M1LodnNCVkeHUh?=
HCT-15	NHu4ZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFu3ZXpKSzVyPUG0Mlg5PTViIN88US=>	NUKzU5RVW0GQR1XS
HCE-T	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE[2[XVKSzVyPUG0Mlg5PzRiIN88US=>	NYrYOVNyW0GQR1XS
SF539	NUPGOlVqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWG3fnVsUUN3ME2xOU4xPjR\|IDFOwG0>	NEPNS3ZUSU6JRWK=
AU565	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\3c21OUUN3ME2xOU4zODl4IDFOwG0>	MmDVV2FPT0WU
JVM-2	NXnje\|FHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LjdGlEPTB;MUWuNlY5OSBizszN	M3:5RXNCVkeHUh?=
CaR-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTF3LkS0NVIhKM7:TR?=	M2Hx[nNCVkeHUh?=
23132-87	Mon3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnnWGZNUUN3ME2xOU45PDl3IDFOwG0>	M1zxNnNCVkeHUh?=
A673	MoXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTF3Lkm2N\|YhKM7:TR?=	Mn;QV2FPT0WU
KYSE-410	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1L4XWlEPTB;MU[uNFI6KCEQvF2=	NYGzcZA1W0GQR1XS
TE-9	NITjb5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLWV5ZNUUN3ME2xOk4xPjJiIN88US=>	MmfhV2FPT0WU
LU-139	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\STWM2OD1zNj6xPFI{KCEQvF2=	NI\zOldUSU6JRWK=
GCIY	MmjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTF4LkG5NVYhKM7:TR?=	M{DJbnNCVkeHUh?=
JEG-3	MkfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1TnU2lEPTB;MU[uNlUhKM7:TR?=	M33Xb3NCVkeHUh?=
RT-112	NHy1dnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mki4TWM2OD1zNj60NVQ{KCEQvF2=	MXvTRW5ITVJ?
COLO-680N	M4rlWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\xcpl4UUN3ME2xOk42OTB6IDFOwG0>	NXH5VXVPW0GQR1XS
LU-134-A	MojJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV[3[olCUUN3ME2xOk46QDl\|IDFOwG0>	NWjIOG5XW0GQR1XS
MFM-223	NXruWJpqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXkSGxKSzVyPUG3MlE2OzViIN88US=>	MYnTRW5ITVJ?
SF126	NVPSPYVwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTF5LkG3NFEhKM7:TR?=	NV7zWIlZW0GQR1XS
NCI-H28	NFLHcoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3;3e2lEPTB;MUeuNlA3PiBizszN	MnXnV2FPT0WU
BFTC-905	Mn;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTF5LkS4N\|IhKM7:TR?=	MVjTRW5ITVJ?
SCC-9	NGHHT4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXrcZpKSzVyPUG3MlYzQDViIN88US=>	MV\TRW5ITVJ?
KNS-62	NV\ucoxJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXzJR\|UxRTF5Lk[2NlkhKM7:TR?=	M4HPSXNCVkeHUh?=
Hs-578-T	MnrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTF5LkixOFkhKM7:TR?=	NHS5enZUSU6JRWK=
D-336MG	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\3ZYZLUUN3ME2xO{45Ojl2IDFOwG0>	M120XnNCVkeHUh?=
NCI-H82	NUjsZ4F1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTF6LkCxPFMhKM7:TR?=	MU\TRW5ITVJ?
EFM-19	MnvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M135RWlEPTB;MUiuNFU4PyBizszN	NXnW[YNqW0GQR1XS
TGBC11TKB	M13XNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzqcIlKSzVyPUG4MlExOjFiIN88US=>	Mmn5V2FPT0WU
HEC-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTF6LkK5NVghKM7:TR?=	MmnuV2FPT0WU
HuP-T3	NHHyR4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3TtNWlEPTB;MUiuOVkzQSBizszN	MkXQV2FPT0WU
SF268	NXPuZpY5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXNT\|M6UUN3ME2xPE43PzB{IDFOwG0>	NFe2S3pUSU6JRWK=
COLO-792	M1v5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTF6Lke5PVchKM7:TR?=	NHjJXFZUSU6JRWK=
HLE	M3S4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfsbWVkUUN3ME2xPE45OzNzIDFOwG0>	MV\TRW5ITVJ?
A204	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\FdGlEPTB;MUiuPVE3PCBizszN	NFvYVnVUSU6JRWK=
CAL-72	NXnmOVV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLzTWM2OD1zOT6wPFc4KCEQvF2=	MUPTRW5ITVJ?
U031	M{[0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPlco9TUUN3ME2xPU41QTB7IDFOwG0>	MkDuV2FPT0WU
FTC-133	M4iwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDYTWM2OD1zOT65N\|A1KCEQvF2=	NF3NcGRUSU6JRWK=
SK-MEL-28	NU\pfnVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDMb2V{UUN3ME2yNE4{PzZzIDFOwG0>	MUnTRW5ITVJ?
KGN	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnnb\|N5UUN3ME2yNE41Pjl7IDFOwG0>	NE\ZO45USU6JRWK=
HCC2998	NV:2SYNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF22XGlKSzVyPUKxMlM6OjZiIN88US=>	MVHTRW5ITVJ?
GOTO	NHnqOYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jLNWlEPTB;MkGuOFg2KCEQvF2=	M4fqN3NCVkeHUh?=
AGS	MlexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTJzLki0OVEhKM7:TR?=	M4TPT3NCVkeHUh?=
EW-13	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3XFOmlEPTB;MkKuNVAzOiBizszN	MV3TRW5ITVJ?
P12-ICHIKAWA	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTJ{LkG2NFMhKM7:TR?=	NIfYSFNUSU6JRWK=
NCI-H1395	M2W3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXO3eGdXUUN3ME2yNk4zQTB5IDFOwG0>	NFX6SHNUSU6JRWK=
A2058	M3Tjb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTJ{LkSzOEAh\|ryP	MkT4V2FPT0WU
SH-4	NWfMXJY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlfQTWM2OD1{Mj63NFQ2KCEQvF2=	NET5bWZUSU6JRWK=
DoTc2-4510	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPQTWM2OD1{Mz62OFczKCEQvF2=	NYriU\|VmW0GQR1XS
MMAC-SF	NYiwbVZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHvTWM2OD1{Mz62PVEyKCEQvF2=	NWjPOIdsW0GQR1XS
NCI-H510A	MorDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTJ\|Lke5N\|khKM7:TR?=	NGf5O3pUSU6JRWK=
HDLM-2	NVLiNGVbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTFNFFiUUN3ME2yOE4yPDZiIN88US=>	M2XWe3NCVkeHUh?=
KINGS-1	NVnhfWV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTJ2LkK0NkAh\|ryP	NVX3To9UW0GQR1XS
NCI-H1648	MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1e1d2lEPTB;MkSuOFAzPCBizszN	M4\EOHNCVkeHUh?=
HCC1187	NHnQPVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2KycmlEPTB;MkWuNFI{PSBizszN	MmTFV2FPT0WU
BALL-1	MlTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnrTWM2OD1{NT6yNFYzKCEQvF2=	NF\hdHNUSU6JRWK=
SBC-1	NWTselVCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPWTWM2OD1{NT6yPVk{KCEQvF2=	MmrYV2FPT0WU
BFTC-909	M1r1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTJ3LkO1OVEhKM7:TR?=	MW\TRW5ITVJ?
MOLT-13	NV\GR2JLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTJ3Lk[3OFQhKM7:TR?=	MkLpV2FPT0WU
SW1990	NUP1SphLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfqPGlKSzVyPUK1Mlk3PTViIN88US=>	MVvTRW5ITVJ?
DK-MG	NVPoZ41lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHm1[WxKSzVyPUK2MlA1PDNiIN88US=>	Mn31V2FPT0WU
TE-8	MoPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfjTWM2OD1{Nj6wOlY5KCEQvF2=	NWPVeJhxW0GQR1XS
Becker	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4q1WmlEPTB;Mk[uNVU4PCBizszN	NXvidZBLW0GQR1XS
KYSE-70	NGjLcWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYT1NotkUUN3ME2yOk42OzF5IDFOwG0>	MnzrV2FPT0WU
MKN7	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVzmNXd6UUN3ME2yO{44PDd7IDFOwG0>	MWjTRW5ITVJ?
D-392MG	M1\Pemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTJ5Lke2PVQhKM7:TR?=	M3T4b3NCVkeHUh?=
NH-12	MorrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkO1TWM2OD1{OD6xNlI6KCEQvF2=	MUHTRW5ITVJ?
EW-18	MmDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDGdoRQUUN3ME2yPE4zOjF6IDFOwG0>	M13TU3NCVkeHUh?=
LCLC-97TM1	MlXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1TNdGlEPTB;MkiuNlc3OiBizszN	NHe5RVlUSU6JRWK=
NCI-H1770	M1rTTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFvBWI9KSzVyPUK4MlM2PjZiIN88US=>	M3fXRnNCVkeHUh?=
BT-20	M2ntXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml7aTWM2OD1{OD6zOlg2KCEQvF2=	MWjTRW5ITVJ?
DBTRG-05MG	NGi1dHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LRdmlEPTB;MkiuOFg{QCBizszN	MnzwV2FPT0WU
HPAF-II	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2e0NmlEPTB;MkiuO\|c6KCEQvF2=	MVzTRW5ITVJ?
SW837	NF;IU5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTJ7LkOzPFUhKM7:TR?=	NGrBUoVUSU6JRWK=
647-V	M2TIfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTJTWM2OD1{OT63NFA{KCEQvF2=	Ml;nV2FPT0WU
J82	NELTdZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HPWWlEPTB;MkmuPFAyOyBizszN	NY\qNGZvW0GQR1XS
MC116	M3v0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3ftcmlEPTB;M{CuNFc{OyBizszN	NFznUolUSU6JRWK=
NCI-H69	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGm0enRKSzVyPUOwMlYxQTNiIN88US=>	NIK5XG9USU6JRWK=
NB6	M4LaOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XQbmlEPTB;M{GuN\|YzQSBizszN	NVnYOpJ3W0GQR1XS
CAL-120	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTN{LkSzNVchKM7:TR?=	M1fROXNCVkeHUh?=
U-87-MG	NILJVHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTN\|LkCyOVEhKM7:TR?=	Mne2V2FPT0WU
NCI-H1304	NEHGS4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1ru[2lEPTB;M{OuNFM2PCBizszN	MoLzV2FPT0WU
YH-13	NFLte\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jaTGlEPTB;M{OuNlU{PSBizszN	NIK4c21USU6JRWK=
RMG-I	NYDpe3JLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfjWoV6UUN3ME2zN{41Ojh3IDFOwG0>	MV;TRW5ITVJ?
LU-65	MojnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHhR\|JKSzVyPUO0MlE1ODhiIN88US=>	M3nGWnNCVkeHUh?=
GB-1	NFy3TVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTN3LkC3NlkhKM7:TR?=	NVLnfXh7W0GQR1XS
DU-4475	M3;FZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4Psc2lEPTB;M{WuNVU2OyBizszN	MYXTRW5ITVJ?
SBC-5	MmXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTN4LkW5NFIhKM7:TR?=	NHXV[nJUSU6JRWK=
OE33	Ml;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHWXmc2UUN3ME2zO{44PTd5IDFOwG0>	NFf5VY5USU6JRWK=
C8166	NXzYfmQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI[3eYhKSzVyPUO4MlUzPjdiIN88US=>	NF3Wb2tUSU6JRWK=
COLO-684	MlPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPJSYZKSzVyPUO4Mlc1OjhiIN88US=>	M{jzdHNCVkeHUh?=
NCI-H1155	MmnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUnpbGU3UUN3ME2zPU4xPDdzIDFOwG0>	NHHSN2JUSU6JRWK=
ATN-1	M1fzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTN7Lke3PVIhKM7:TR?=	NHnieW1USU6JRWK=
KARPAS-299	NWXEUZdHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\5TWM2OD1\|OT64N\|khKM7:TR?=	MXrTRW5ITVJ?
KNS-81-FD	MkPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTRyLkO2NFQhKM7:TR?=	NXPSdW15W0GQR1XS
NCI-H1563	NVzGbmNrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFnsZm5KSzVyPUSxMlUxOzliIN88US=>	MnnWV2FPT0WU
NB14	M{Xtb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{PKZmlEPTB;NEKuO\|I3OyBizszN	M4TQe3NCVkeHUh?=
COLO-800	MlTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrrWoZ5UUN3ME20Nk45PTF5IDFOwG0>	NH20bW5USU6JRWK=
MS-1	MnLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoS4TWM2OD12Mz6wOFg{KCEQvF2=	NULCRmRbW0GQR1XS
OVCAR-8	Mn;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHjacoFKSzVyPUSzMlY5ODliIN88US=>	NFTIUVlUSU6JRWK=
SK-PN-DW	NUTRXWpkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTR\|Lki3O\|YhKM7:TR?=	NWD6bHcyW0GQR1XS
G-402	NW\ZXFgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnuTWM2OD12Mz65NFA3KCEQvF2=	MnzFV2FPT0WU
NCI-H2291	MlfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVn6RW5UUUN3ME20OE45ODF5IDFOwG0>	Mn\uV2FPT0WU
PC-3	NXzRcIJYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXMRVFJUUN3ME20OU45ODJ\|IDFOwG0>	MWfTRW5ITVJ?
NCI-H1581	MlfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnYTWM2OD12NT65PFg6KCEQvF2=	NIe3U3dUSU6JRWK=
SW1116	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7mNHZKSzVyPUS3MlAyQDJiIN88US=>	NIra[JJUSU6JRWK=
ZR-75-30	NHnHOG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;Fd\|dKSzVyPUS3MlAzOzliIN88US=>	M1HVWXNCVkeHUh?=
OCI-AML2	M4TXV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzwOJNZUUN3ME20O{4xQTF6IDFOwG0>	MWHTRW5ITVJ?
MDA-MB-231	M2TrR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWT3PVd5UUN3ME20O{43OjR7IDFOwG0>	NVvRWG82W0GQR1XS
ES3	MoSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1Ty[mlEPTB;NEiuN\|UzQSBizszN	Mk\lV2FPT0WU
NCI-H630	M2Tlc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fM[mlEPTB;NEmuNVc1OiBizszN	M2KwV3NCVkeHUh?=
OE19	M4nRUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTR7LkK5NFIhKM7:TR?=	NHHtVYpUSU6JRWK=
NCI-H1573	M365OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XCSGlEPTB;NEmuOlg3OSBizszN	NF21cXNUSU6JRWK=
EW-1	MmG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2DzUGlEPTB;NEmuPVA5PCBizszN	NWD2U2JjW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo

Bosutinib (60 mg/kg/day) is active against Src-transformed fibroblasts xenografts and HT29 xenografts in nude mice with T/C of 18% and 30%, respectively. ^[1] Oral administration of Bosutinib for 5 days significantly suppresses K562 tumor growth in mice in a dose-dependent manner, with the large tumors eradicated at dose of 100 mg/kg and tumor free at 150 mg/kg without overt toxicity. ^[2] As being inactive against Colo205 xenografts in nude mice at 50 mg/kg twice daily, Bosutinib dosing at 75 mg/kg twice daily is necessary against Colo205 xenografts, and increasing the dose of Bosutinib has no additional benefit, in contrast to the significant dose-dependent ability against HT29 xenografts. ^[4]

Protocol

Kinase Assay: ^[1]	+ Expand The Src and Abl kinase assays: The Src kinase activity is measured in an ELISA format. Src (3 units/reaction), reaction buffer (50 mM Tris-HCl pH 7.5, 10 mM MgCl₂, 0.1 mM EGTA, 0.5 mM Na₃VO₄) and cdc2 substrate peptide are added to various concentration of Bosutinib and incubated at 30 °C for 10 minutes. The reaction is started by the addition of ATP to a final concentration of 100 μM, incubated at 30 °C for 1 hour and stopped by addition of EDTA. Instructions from the manufacturer are followed for subsequent steps. The Abl kinase assay is performed in a DELFIA solid phase europium-based detection assay format. Biotinylated peptide (2 μM) is bound to streptavidin-coated microtitration plates for 1.5 hours in 1 mg/mL ovalbumin in PBS. The plates are washed for 1 hour with PBS/0.1% Tween 80, followed by a PBS wash. The kinase reaction is incubated for 1 hour at 30°C. Abl kinase (10 units) is mixed with 50 mM Tris-HCl (pH 7.5), 10 mM MgCl₂, 80 μM EGTA, 100 μM ATP, 0.5 mM Na₃VO₄, 1% DMSO, 1 mM HEPES (pH 7.0), 200 μg/mL ovalbumin and various concentration of Bosutinib. The reaction is stopped with EDTA at a final concentration of 50 mM. The reaction is monitored with Eu-labeled phosphotyrosine antibody and DELFIA enhancement solution.
Cell Research: ^[2]	+ Expand Cell lines: Abl-MLV, Rat 2, KU812, K562, and MEG-01 cells Concentrations: Dissolved in DMSO, final concentrations ~1 μM Incubation Time: 72 hours Method: Cells are exposed to various concentrations of Bosutinib for 72 hours. Anchorage-independent proliferation of Abl-MLV-transformed fibroblasts is measured in 96-well ultra-low binding plates treated with Sigmacote to block residual cell attachment. Cell proliferation is measured with MTS or Cell-Glo. For the determination of cell cycle or cell death, cells are prepared for FACS analysis in the CycleTest Plus DNA reagent kit and analyzed on a fluorescence-activated cell sorter flow cytometer. (Only for Reference)
Animal Research: ^[2]	+ Expand Animal Models: Nude female mice injected with K562 cells Formulation: Suspended in 0.5% methocel/0.4% Tween 80 Dosages: ~150 mg/kg/day Administration: Oral gavage (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	100 mg/mL (188.51 mM)
	Ethanol	2 mg/mL (3.77 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Bosutinib (SKI-606) SDF

Molecular Weight	530.45
Formula	C₂₆H₂₉Cl₂N₅O₃
CAS No.	380843-75-4
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03106779	Recruiting	Chronic Myelogenous Leukemia	Novartis Pharmaceuticals\|Novartis	October 26 2017	Phase 3
NCT03297606	Recruiting	Lymphoma Non-Hodgkin\|Multiple Myeloma\|Advanced Solid Tumors	Canadian Cancer Trials Group\|AstraZeneca\|Bristol-Myers Squibb\|Hoffmann-La Roche\|Pfizer	October 6 2017	Phase 2
NCT03128411	Active not recruiting	Leukemia Chronic Myelogenous	Pfizer	May 15 2017	Phase 2
NCT02782403	Recruiting	Leukemia	M.D. Anderson Cancer Center\|Pfizer	March 20 2017	Phase 1\|Phase 2
NCT03023319	Recruiting	Carcinoma Non-Small-Cell Lung\|Mesothelioma\|Bladder Cancer\|Ovarian Cancer\|Peritoneal Cancer\|Thymoma\|Thymus Cancer\|Uterine Cervical Cancer	Nagla Karim\|University of Cincinnati	January 2017	Phase 1
NCT02810990	Recruiting	Chronic Myeloid Leukemia	Gruppo Italiano Malattie EMatologiche dell''Adulto	November 2016	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Can I give S1014 Bosutinib to mice by oral gavage? If so, how to dissolve the drug?
Answer:
For oral gavage, S1014 Bosutinib can be dissolved in 5% Tween 80+0.5% CMC Na at 30 mg/ml as a suspension.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Most Potent Src Inhibitor

Dasatinib : Src, IC50=0.8 nM.
FDA-approved Src Inhibitor

Dasatinib : Approved by FDA for CML and Ph+ ALL.
Newest Src Inhibitor

PP1 : Potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
Classic Src Inhibitor

KX2-391 : The first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

Related Src Products4

Dasatinib Monohydrate ^New

Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.
SU6656 ^New

SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.
PX-478 2HCl ^New

PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.
Saracatinib (AZD0530)

Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Phase 2/3.

Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.
Dasatinib

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
KX2-391

KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.
PP1

PP1 is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
PP2

PP2, a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.
WH-4-023

WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50s of 2 nM and 6 nM in cell-free assays, respectively. Exhibits >300-fold selectivity against p38α and KDR. Also potently inhibits SIK (IC50 values are 10, 22 and 60 nM for SIK 1, 2 and 3 respectively) and displays selectivity over a range of closely related kinases.
Ibrutinib (PCI-32765)

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.

Choose Your Country or Region

By Signaling Pathways

By product type

Bosutinib (SKI-606)

Cited by 19 Publications

5 Customer Reviews

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Bosutinib (SKI-606) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

Tech Support

Frequently Asked Questions

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products4

Choose Your Country or Region

By Signaling Pathways

By product type

Bosutinib (SKI-606)

Cited by 19 Publications

5 Customer Reviews

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Bosutinib (SKI-606) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

Tech Support

Frequently Asked Questions

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)